Advanced RNA Delivery Systems for Enhanced Immune Responses

The invention presents a next-generation RNA delivery system that leverages self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells to induce robust and systemic immune responses.

The original patent introduced a non-viral delivery of RNA for immunization using liposomes and mRNA molecules. However, the technology had limitations in terms of targeted delivery, immune response, and scalability. The new inventive concept addresses these limitations by introducing self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells, enabling more efficient and effective immune responses.

The advanced RNA delivery system comprises RNA replicons that self-amplify and express an immunogen, encapsulated in a nanoparticle featuring a synthetic lipid bilayer. This design enables targeted delivery to antigen-presenting cells, enhancing the immune response. The system can be further optimized by incorporating toll-like receptor agonists to amplify the immune response. The inventive concept also encompasses vaccine compositions combining multiple RNA replicons that self-amplify and express different immunogens, providing a robust and adaptive immune response.

The new inventive concept introduces the use of self-amplifying mRNA, synthetic lipid bilayers, and targeted delivery to antigen-presenting cells, which significantly improves the efficiency and effectiveness of RNA delivery for immunization. These advancements provide a paradigm shift in the field, making the original inventive concept obsolete.

Alternative embodiments of the inventive concept could include the use of different types of nanoparticles, varying the composition of the synthetic lipid bilayer, or incorporating additional immune stimulants. Variations could also involve adapting the system for different immunogens or disease targets, such as cancer or infectious diseases.

The advanced RNA delivery system has significant commercial potential in the vaccine and immunotherapy markets, offering a more efficient and effective approach to inducing immune responses. The technology could be applied to various disease areas, including infectious diseases, cancer, and autoimmune disorders, providing a substantial market opportunity.